Arbor Biotechnologies

Executive Summary

Arbor Biotechnologies is a privately held genetic medicines company headquartered in Cambridge, Massachusetts, leveraging a proprietary toolbox of novel CRISPR-based DNA editors to develop curative therapies for a broad range of genetic diseases. Founded in 2016, the company has built a diverse platform of programmable nucleases, including CRISPR-Cas9 and beyond, enabling precision editing across various tissues and delivery modalities. Arbor's approach focuses on creating functional cures by directly correcting disease-causing mutations, with an initial emphasis on liver and central nervous system disorders. The company’s pipeline, though early-stage, targets indications with high unmet need and clear genetic etiologies, positioning it to capitalize on the growing demand for in vivo gene editing solutions. With a strong scientific foundation and strategic partnerships, Arbor aims to advance its lead programs toward clinical development in the near term.

Upcoming Catalysts (preview)

• Q2 2026Series C financing round to advance pipeline75% success
• Q4 2026IND filing for lead in vivo gene editing program40% success
• Q1 2027Preclinical proof-of-concept data for CNS program50% success